Cardiovascular complications are among the main reasons for the high morbidity and mortality
in patients with type 2 diabetes, making the management of cardiovascular complications an integral
component in the treatment of type 2 diabetes. Along the same line, the US Food and Drug Administration
mandated all new diabetic drugs and therapies have a safe cardiovascular profile. Among various
drugs available for the treatment against type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT2)
inhibitors represent a class of newly developed anti-diabetic agents with properties of mitigating cardiovascular
risk in patients with type 2 diabetes. Evidence from clinical trials has suggested that the SGLT2
inhibitors empagliflozin and canagliflozin are capable of reducing the overall risk of cardiovascular
events and mortality in type 2 diabetic patients. In this mini-review, we will briefly discuss the various
cardiovascular benefits of SGLT2 inhibitors, and the underlying mechanisms involved.
Keywords: SGLT2, GLP-1, DPP-4, type 2 diabetes, cardiovascular, clinical.
Rights & PermissionsPrintExport